It happens with regularity during citizen open-mike sessions at FDA drug advisory committee hearings. A queue of “patients” materializes out of nowhere to testify, often in tears, about the crucial ...

Royalty Pharma purchases royalties on pharmaceutical products. Diversification provides some protection for investors and the company has invested in high quality assets. Investors face risks ...

Traditionally, pharmaceutical companies’ interactions with healthcare professionals (HCPs) have been highly personalized — primarily via face-to-face, in-office visits. Recently, however, this model ...

Forbes contributors publish independent expert analyses and insights. I write about business model strategy and execution across healthcare. The pharmaceutical industry is in the midst of profound ...

At a time when patients demand greater transparency and control over their health journey, patient engagement is no longer a ...

Details: Pharmaceutical companies face a fundamental decision about the best way to sell their products. Even if they could find a way to make the current sales model work, pharma companies still face ...

Merck CEO Kenneth Frazier said last week that he wants to publicly dissociate innovative pharmaceutical companies like Merck from Turing Pharmaceuticals, the drugmaker criticized for raising the price ...

Just when the appetite for European biotech was showing signs of a healthy recovery from the 2001 venture fallout, along comes a recession. But with LP appetite for the buyout market at an all-time ...

BridgeBio Pharma, Inc. has a lot of irons in the fire. Despite BridgeBio Pharma, Inc. getting approvals for two products, there's hardly any revenue. None of the BridgeBio Pharma, Inc. products stand ...

PHILADELPHIA--(BUSINESS WIRE)--Big Pharma's dependence on traditional executive compensation plans threatens to work in opposition to the very "medicine" of innovation that could restore the sector's ...

Forbes contributors publish independent expert analyses and insights. I write about business model strategy and execution across healthcare. When the Trump administration dropped the drug rebate rule ...

Influenza Artificial Intelligence model build completedCytoReason analysis of human challenge trial data on track to deliver outputs in Q2 2023 LONDON, UK / ACCESSWIRE / November 29, 2022 / Poolbeg ...